Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.

Newman EA, Chukkapalli S, Bashllari D, Thomas TT, Van Noord RA, Lawlor ER, Hoenerhoff MJ, Opipari AW, Opipari VP.

Cell Death Dis. 2017 Dec 13;8(12):3208. doi: 10.1038/s41419-017-0004-9.

2.

Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.

Newman EA, Lu F, Bashllari D, Wang L, Opipari AW, Castle VP.

Mol Cancer Res. 2015 Mar;13(3):470-82. doi: 10.1158/1541-7786.MCR-14-0337. Epub 2015 Jan 6.

3.

MYCN induces neuroblastoma in primary neural crest cells.

Olsen RR, Otero JH, García-López J, Wallace K, Finkelstein D, Rehg JE, Yin Z, Wang YD, Freeman KW.

Oncogene. 2017 Aug 31;36(35):5075-5082. doi: 10.1038/onc.2017.128. Epub 2017 May 1.

4.

MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.

Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Künkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, Schramm A.

Oncogene. 2013 Feb 21;32(8):1059-65. doi: 10.1038/onc.2012.106. Epub 2012 Apr 9.

PMID:
22484425
5.

Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.

Kramer M, Ribeiro D, Arsenian-Henriksson M, Deller T, Rohrer H.

J Neurosci. 2016 Oct 5;36(40):10425-10439.

6.

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.

Hallett RM, Seong AB, Kaplan DR, Irwin MS.

Mol Oncol. 2016 Nov;10(9):1461-1472. doi: 10.1016/j.molonc.2016.07.012. Epub 2016 Aug 18.

7.

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, Civin C, Scheibner K, Rassool FV.

Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.

8.

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.

Colicchia V, Petroni M, Guarguaglini G, Sardina F, Sahún-Roncero M, Carbonari M, Ricci B, Heil C, Capalbo C, Belardinilli F, Coppa A, Peruzzi G, Screpanti I, Lavia P, Gulino A, Giannini G.

Oncogene. 2017 Aug 17;36(33):4682-4691. doi: 10.1038/onc.2017.40. Epub 2017 Apr 10.

PMID:
28394338
9.

Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.

Zaatiti H, Abdallah J, Nasr Z, Khazen G, Sandler A, Abou-Antoun TJ.

Int J Oncol. 2018 Mar;52(3):787-803. doi: 10.3892/ijo.2018.4236. Epub 2018 Jan 4.

10.

MYCN-amplified neuroblastoma maintains an aggressive and undifferentiated phenotype by deregulation of estrogen and NGF signaling.

Dzieran J, Rodriguez Garcia A, Westermark UK, Henley AB, Eyre Sánchez E, Träger C, Johansson HJ, Lehtiö J, Arsenian-Henriksson M.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1229-E1238. doi: 10.1073/pnas.1710901115. Epub 2018 Jan 26.

11.

Expression of MYCN in Multipotent Sympathoadrenal Progenitors Induces Proliferation and Neural Differentiation, but Is Not Sufficient for Tumorigenesis.

Mobley BC, Kwon M, Kraemer BR, Hickman FE, Qiao J, Chung DH, Carter BD.

PLoS One. 2015 Jul 29;10(7):e0133897. doi: 10.1371/journal.pone.0133897. eCollection 2015.

12.

Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.

Chen Z, Lin Y, Barbieri E, Burlingame S, Hicks J, Ludwig A, Shohet JM.

Neoplasia. 2009 Aug;11(8):753-62.

13.

MYCN gene expression is required for the onset of the differentiation programme in neuroblastoma cells.

Guglielmi L, Cinnella C, Nardella M, Maresca G, Valentini A, Mercanti D, Felsani A, D'Agnano I.

Cell Death Dis. 2014 Feb 20;5:e1081. doi: 10.1038/cddis.2014.42.

14.

CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.

Zhao X, Li D, Pu J, Mei H, Yang D, Xiang X, Qu H, Huang K, Zheng L, Tong Q.

Oncogene. 2016 Jul 7;35(27):3565-76. doi: 10.1038/onc.2015.422. Epub 2015 Nov 9.

PMID:
26549029
15.

MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.

Xue C, Yu DM, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, London WB, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD.

Oncotarget. 2016 Aug 23;7(34):54937-54951. doi: 10.18632/oncotarget.10709.

16.

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.

Murakami-Tonami Y, Ikeda H, Yamagishi R, Inayoshi M, Inagaki S, Kishida S, Komata Y, Jan Koster, Takeuchi I, Kondo Y, Maeda T, Sekido Y, Murakami H, Kadomatsu K.

Sci Rep. 2016 Aug 19;6:31615. doi: 10.1038/srep31615.

17.

MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development.

Alam G, Cui H, Shi H, Yang L, Ding J, Mao L, Maltese WA, Ding HF.

Am J Pathol. 2009 Aug;175(2):856-66. doi: 10.2353/ajpath.2009.090019. Epub 2009 Jul 16.

18.

Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn.

Kobayashi K, Jakt LM, Nishikawa SI.

Oncogene. 2013 May 23;32(21):2640-8. doi: 10.1038/onc.2012.285. Epub 2012 Jul 2.

19.

The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.

O'Brien EM, Selfe JL, Martins AS, Walters ZS, Shipley JM.

BMC Cancer. 2018 Feb 21;18(1):217. doi: 10.1186/s12885-018-4129-8.

20.

Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.

He J, Gu L, Zhang H, Zhou M.

Cell Cycle. 2011 Sep 1;10(17):2994-3002. Epub 2011 Sep 1.

Supplemental Content

Support Center